Like I said, management needs to follow up on statements ...or lose credibility.
From March 4 2021 release. So what is the status?
“We’ve built up a knowledge base for European growing practices and are using the Campus to fine-tune our value proposition and fast-track our launch,” said Mr. Lehnen. “The Swiss regulatory approval process is in advanced stages with requests from the authorities having been answered with reasoned cases; and we can use the work we’ve done there for BVT’s eventual EU regulatory submission.” BVT is working with regulatory consultants in Europe to develop the best strategy to pursue submission for the EU regulatory approval process of its proprietary biological plant protection product CR-7 (Clonostachys rosea strain CR-7). The Company could kick start EU submission later in 2021 depending on the outcome of the current exploratory phase.“Securing approval of our own plant protection product for use in the EU will represent a significant value creation milestone,” said Ashish Malik, CEO of Bee Vectoring Technologies. “This will not only represent a significant asset for the Company, but will also provide BVT with the flexibility to pursue different licensing arrangements (including licensing CR-7 out to companies in other markets) and not be wholly reliant on access to products from third parties.”